Last reviewed · How we verify
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 (Cohort 1: hATG, CsA, EPAG Day 14 to Month 6) — National Heart, Lung, and Blood Institute (NHLBI).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 TARGET | Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 | National Heart, Lung, and Blood Institute (NHLBI) | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 CI watch — RSS
- Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 CI watch — Atom
- Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 CI watch — JSON
- Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 alone — RSS
Cite this brief
Drug Landscape (2026). Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 — Competitive Intelligence Brief. https://druglandscape.com/ci/cohort-1-hatg-csa-epag-day-14-to-month-6. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab